- Home
- DRH vs GLPG Comparison
DRH vs GLPG Comparison
Compare DRH & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRH
- GLPG
- Stock Information
- Founded
- DRH 2004
- GLPG 1999
- Country
- DRH United States
- GLPG Belgium
- Employees
- DRH N/A
- GLPG N/A
- Industry
- DRH Real Estate Investment Trusts
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- DRH Real Estate
- GLPG Health Care
- Exchange
- DRH Nasdaq
- GLPG Nasdaq
- Market Cap
- DRH 1.7B
- GLPG 2.1B
- IPO Year
- DRH 2005
- GLPG 2005
- Fundamental
- Price
- DRH $7.89
- GLPG $32.72
- Analyst Decision
- DRH Hold
- GLPG Sell
- Analyst Count
- DRH 6
- GLPG 3
- Target Price
- DRH $8.63
- GLPG $26.00
- AVG Volume (30 Days)
- DRH 2.6M
- GLPG 222.3K
- Earning Date
- DRH 11-06-2025
- GLPG 11-03-2025
- Dividend Yield
- DRH 4.14%
- GLPG N/A
- EPS Growth
- DRH N/A
- GLPG N/A
- EPS
- DRH 0.28
- GLPG N/A
- Revenue
- DRH $1,124,753,000.00
- GLPG $323,674,692.00
- Revenue This Year
- DRH N/A
- GLPG $1.77
- Revenue Next Year
- DRH $2.31
- GLPG $0.44
- P/E Ratio
- DRH $27.74
- GLPG N/A
- Revenue Growth
- DRH 1.72
- GLPG 5.43
- 52 Week Low
- DRH $6.19
- GLPG $22.36
- 52 Week High
- DRH $10.00
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- DRH 49.64
- GLPG 44.78
- Support Level
- DRH $7.60
- GLPG $33.91
- Resistance Level
- DRH $7.85
- GLPG $35.00
- Average True Range (ATR)
- DRH 0.16
- GLPG 0.88
- MACD
- DRH 0.02
- GLPG -0.21
- Stochastic Oscillator
- DRH 68.73
- GLPG 28.85
About DRH Diamondrock Hospitality Company
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.